Vecta Pharmaceuticals · raw details

Vecta Pharmaceuticals develops pharmaceutical treatments for upper GI tract diseases. The company's flagship product, VECAM-111, is designed toaddress symptoms of gastroesophageal reflux disease (GERD) that are not addressed by existing therapeutic options. VECAM-111 is an improved proton pump inhibitor (PPI). VECAM-111 offersdaytime and nighttime dosing flexibility and nocturnal efficacy. The drug also eliminates the need for food to make PPIs work effectively. VECAM-111 uses pharmacological stimulation in an all-in-one solution that includes the necessary ingredients to stimulate proton pumps and treat GERD. VECAM-111 capsules consist of an inner capsule of succinic acid (SA) and an outer layer of an enteric-coated PPI, esomeprazole. The outer shell dissolves after the drug is swallowed and the PPI is absorbed. This formulation ensures that the PPI is present in the system when the inner SA capsule is dissolved and stimulates activity.